4//SEC Filing
venBio Global Strategic Fund, L.P. 4
Accession 0000905148-20-001037
CIK 0001634379other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 5:21 PM ET
Size
18.1 KB
Accession
0000905148-20-001037
Insider Transaction Report
Form 4
Metacrine, Inc.MTCR
venBio Global Strategic Fund, L.P.
10% OwnerOther
Transactions
- Conversion
Common Stock
2020-09-18+2,829,123→ 3,059,123 total - Purchase
Common Stock
2020-09-18$13.00/sh+230,000$2,990,000→ 230,000 total - Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total→ Common Stock (1,960,784 underlying) - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,250→ 0 total→ Common Stock (472,250 underlying) - Conversion
Series C Convertible Preferred Stock
2020-09-18−396,089→ 0 total→ Common Stock (396,089 underlying)
venBio Global Strategic GP, Ltd.
10% OwnerOther
Transactions
- Conversion
Common Stock
2020-09-18+2,829,123→ 3,059,123 total - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,250→ 0 total→ Common Stock (472,250 underlying) - Conversion
Series C Convertible Preferred Stock
2020-09-18−396,089→ 0 total→ Common Stock (396,089 underlying) - Purchase
Common Stock
2020-09-18$13.00/sh+230,000$2,990,000→ 230,000 total - Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total→ Common Stock (1,960,784 underlying)
GOODMAN COREY S
10% OwnerOther
Transactions
- Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total→ Common Stock (1,960,784 underlying) - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,250→ 0 total→ Common Stock (472,250 underlying) - Conversion
Common Stock
2020-09-18+2,829,123→ 3,059,123 total - Purchase
Common Stock
2020-09-18$13.00/sh+230,000$2,990,000→ 230,000 total - Conversion
Series C Convertible Preferred Stock
2020-09-18−396,089→ 0 total→ Common Stock (396,089 underlying)
venBio Global Strategic GP, L.P.
10% OwnerOther
Transactions
- Conversion
Series A Convertible Preferred Stock
2020-09-18−1,960,784→ 0 total→ Common Stock (1,960,784 underlying) - Conversion
Series C Convertible Preferred Stock
2020-09-18−396,089→ 0 total→ Common Stock (396,089 underlying) - Conversion
Common Stock
2020-09-18+2,829,123→ 3,059,123 total - Purchase
Common Stock
2020-09-18$13.00/sh+230,000$2,990,000→ 230,000 total - Conversion
Series B Convertible Preferred Stock
2020-09-18−472,250→ 0 total→ Common Stock (472,250 underlying)
Footnotes (2)
- [F1]Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- [F2]The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Documents
Issuer
Metacrine, Inc.
CIK 0001634379
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001504130
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 5:21 PM ET
- Size
- 18.1 KB